Highlights Ocean Biomedical, Inc.

Equities

OCEA

US67644C1045

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-07 EDT			5-day change	1st Jan Change
1.445 ^USD	-0.69%		-1.70%	+118.94%

05-30	Ocean Biomedical Gets Nasdaq Noncompliance Notice; Shares Down	MT
04-15	Ocean Biomedical, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Ocean Biomedical, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	04-15	CI
North American Morning Briefing : S&P 500 Futures -2-	02-23	DJ
North American Morning Briefing : S&P 500 Futures Dip with Fresh Record in Sight	12-20	DJ
Ocean Biomedical Announces Publication of Breast Cancer Research Uncovering New Tumor Suppression Pathway for its Proprietary Anti-Chi3L1 Antibody	12-05	CI
Ocean Biomedical Receives Non-Compliance Notice From Nasdaq	11-30	MT
Ocean Biomedical, Inc. Announces Positive Preclinical Oncology Data for Vron 0300, Presented At Sitc 2023 Annual Meeting, and Clinical Updates by 50/50 Joint Venture Partner Virion Therapeutics	11-14	CI
Virion Therapeutics and Joint Venture Partner, Ocean Biomedical Announces First Patients Dosed with Novel Immunotherapy Evaluating A Functional Cure for Chronic Hepatitis B Virus Infection	23-10-26	CI
Ocean Biomedical, Virion Therapeutics Form Joint Venture to Seek Cures for Cancer, Infectious Diseases	23-10-12	MT
Ocean Biomedical Announces Newly Published Findings Demonstrating Ability to Restore Treatment Sensitivity to Astrazeneca?s Leading Lung Cancer Drug After Resistance Has Formed, and Enhanced Tumor Suppression in EGFR-Mutation Lung Cancers	23-10-03	CI
Ocean Biomedical, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Ocean Biomedical, Inc. Provides Latest Updates on Its Broad Programs in Malaria, Fibrosis, and Multiple Cancers	23-08-10	CI
Ocean Biomedical, Inc. Focuses its Multi-Ponged Malaria Program to Address the Chronic Malaria Crisis in Sub-Saharan Africa	23-07-11	CI
Ocean Biomedical Receives European Patent Notice for Idiopathic Pulmonary Fibrosis Treatment Candidate	23-06-23	MT
Ocean Biomedical Extends Patent Rights for Breakthrough Idiopathic Pulmonary Fibrosis Discovery to Europe	23-06-23	CI
Ocean Biomedical, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-24	CI
Ocean Biomedical's Scientific Co-Founder Issued Patent for Cancer Immunotherapy Treatment	23-05-23	MT
Ocean Biomedical, Inc. Announces Patent Award for Novel Cancer Immunotherapy Treatment, Granted for Prostate Cancer, Colon Cancer, Ovarian Cancer, Kidney Cancer, Breast Cancer, Glioblastoma, Melanoma, and Lung Cancer	23-05-23	CI
Ocean Biomedical, Inc. Announces Notice of Allowance for U.S. Patent Application for Breakthrough Pulmonary Fibrosis Treatments Issued to Scientific Co-Founder Dr. Jack A. Elias	23-04-20	CI
Ocean Biomedical's Scientific Co-Founder Jonathan Kurtis Receives Notice of Allowance From USPTO for Malaria Therapeutics	23-04-13	MT
Ocean Biomedical, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Ocean Biomedical, Inc.

Equities

OCEA

US67644C1045

Highlights

Filters